CryoCor is requesting that the ITC initiate an investigation and issue an exclusion order to bar the importation into the US of infringing CryoCath cryoablation products. CryoCor’s complaint covers three patents exclusively licensed to CryoCor in certain fields of use related to its Cardiac Cryoablation System, including patents covering pre-cooling technologies that CryoCor considers important to CryoCath’s cryoablation system.
Ed Brennan, president and CEO of CryoCor, said: “Our request for this investigation further reinforces our strategy to protect our intellectual property rights. Importantly, an ITC investigation has a fast timeline for completion, usually just over one year. If we prevail, the ITC may issue a ban on importation of CryoCath’s cryoablation system into the US. We expect to hear from the ITC within 30 days and will provide an update upon their response.”